Abstract:: Immunotherapies, especially immune checkpoint blockade therapy have shown unprecedented clinical benefits in several malignancies, however, responses are variable emphasizing the need for effective biomarkers for patient stratification 1 . Phenotyping of tumors into hot, altered, or cold 2 based on T-lymphocyte infiltration in tumor biopsies fails to explain and/or predict response to immunotherapy seen in a subset of patients 3,4 . One of the primary reasons for this suboptimal prediction by a single immune marker could be attributed to the fact that additional mechanisms within the tumor microenvironment modulate anti-tumor immunity and outcomes, including dynamic events such as tumor-angiogenesis and leukocyte trafficking 2,5,6 . We report novel tumor phenotypes through non-invasive spatially-resolved cellular-level analysis of the tumor immune microenvironment (TiME) and major determinants of anti-tumor immunity. Using skin cancers as a model and optical imaging using reflectance confocal microscopy (RCM) 7 , we determined four major phenotypes based on unsupervised clustering for relative prevalence of vasculature (Vasc) and inflammation (Inf) features: Vasc high Inf high , Vasc high Inf low , Vasc low Inf(intratumoral) high and Vasc mod Inf low . The Vasc high Inf high phenotype correlate with high immune and vascular signatures while Vasc high Inf low with endothelial anergy. Automated quantification of TiME features demonstrates moderate accuracy and high correlation with corresponding gene expression. Prospective testing of TiME features prior to topical immunotherapy response shows highest response in the Vasc low Inf(IT) high phenotype, and revealing the added value of vascular features in predicting treatment response. This novel in vivo phenotyping combining dynamic immune and vascular features has the potential to advance fundamental understanding of the highly dynamic TiME, identify novel druggable pathways and develop robust predictors for immunotherapy outcomes. Towards addressing the dynamic, complex and highly interdependent vascular-inflammation axis inside the TiME, in vivo phenotyping based on a combination of dynamic vascular and immune features, rather than ex vivo phenotyping based on static pathological evaluation of tumor infiltrating cells may facilitate a deeper understanding and achieve higher predictive power for patient stratification for immunotherapies. High-resolution non-invasive in vivo imaging is fundamental to this combination phenotyping, since static ex vivo analyses on patient tissue are limited in recapitulating dynamic vascular and immune attributes 19 . We report novel combination phenotypes detected in vivo using reflectance confocal microscopic (RCM) imaging. RCM is a high-speed (pixel times ~ 0.10 µsec, frame rates 10-30 per second) cellular-level label-free imaging approach based on backscattered light and endogenous tissue contrast 7,20 . Large image mosaics (64 mm 2 in 50 seconds) imaged to a depth of ~0.25 mm enables spatial resolution of TiME features. RCM is routinely used for real-time skin cancer diagnosis and management at the bedside. Few studies have demonstrated RCM imaging of vessels and leukocyte trafficking in humans 21,22 . Using skin cancer as a model, we define novel combination TiME phenotypes using six features: vessel diameter, vessel density, leukocyte trafficking, intratumoral inflammation, peritumoral inflammation and perivascular inflammation (Fig S1) and report their subsequent molecular correlation with inflammatory, angiogenic and trafficking signatures. We also and, in a prospective pilot study, examine their investigated relative importance of TiME features in predicting response to topical immunotherapy. TLS-negative (p<0.001) anti-tumor I. Higher TLS coverage (>0.1 mm2) correlated with higher TILs (p<0.001); Higher TLS area coverage was associated with a statistically higher probability of tumor killing.

Phenotyping the human tumor-immune microenvironment (TiME) in vivo by cellular-level optical imaging reveals unique combination phenotypes with variable inflammation and endothelial anergy

Cellular-level Phenotyping of Tumor-Immune Microenvironment (time) in Patients in Vivo Reveals Distinct Inflammation and Endothelial Anergy Signatures

Phenotyping Human Tumor Immune Microenvironment (time) in Vivo in Patients to Predict Response to Immunotherapy

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

Abstract 6872: A spatio-temporal approach to mapping the dynamics of cutaneous squamous cell carcinoma progression and immunotherapy response: A journey through TiME

Multiomic Spatial Phenotyping of the Tumor Immune Microenvironment at Single Cell Resolution

Abstract 5626: Multiomic spatial profiling of the tumor immune microenvironment at single cell resolution

Deep Computational Image Analysis of Immune Cell Niches Reveals Treatment-Specific Outcome Associations in Lung Cancer

Multiplexed Imaging Mass Cytometry Reveals Distinct Tumor-Immune Microenvironments Linked to Immunotherapy Responses in Melanoma

Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments

Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues

Based on Scrna-Seq and Bulk RNA-seq to Establish Tumor Immune Microenvironment-Associated Signature of Skin Melanoma and Predict Immunotherapy Response

Abstract 905: ML quantification of tumor-Infiltrating lymphocytes distinguishes immune-phenotypes and reveals phenotypic heterogeneity

Abstract 6179: Machine learning (ML)-spatial quantification of the tumor microenvironment (TME) identifies differences associated with response to bintrafusp alfa (BA) vs pembrolizumab (PEM) treatment in the Phase 3 INTR@PID Lung 037 study

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Spatially Resolved Analyses Link Genomic and Immune Diversity and Reveal Unfavorable Neutrophil Activation in Melanoma

Abstract 1158: Spatially resolved cell profiling unveils tumor metabolic states associated with immunotherapy response in NSCLC

Abstract 2389: In vivo multiphoton autofluorescence imaging is sensitive to CD8 T cell and tumor cell metabolic changes during immunotherapy in a murine melanoma model

Abstract 1714: Profiling spatial signatures in the microenvironment of non-small cell lung carcinomas in immunotherapy responsive and resistant disease cohorts

Assessing the Tumor Immune Landscape Across Multiple Spatial Scales to Differentiate Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer

492 Integration of High Dimensional Datasets in an Immunocompetent Mammary Mouse Model Reveals Pathways of Tolerance and Resistance to Immune Checkpoint Blockade